Search

Your search keyword '"Tewari, Krishnansu S."' showing total 940 results
Start Over Author "Tewari, Krishnansu S."
940 results on '"Tewari, Krishnansu S."'

203. Implementation of human papillomavirus video education for women participating in mass cervical cancer screening in Tanzania

Author

Cooper, Emma C., primary, Maher, Justine A., additional, Naaseh, Ariana, additional, Crawford, Elizabeth W., additional, Chinn, Justine O., additional, Runge, Ava S., additional, Lucas, Alexa N., additional, Zezoff, Danielle C., additional, Bera, Kevin R., additional, Dinicu, Andreea I., additional, White, Kayla M., additional, Tewari, Sujata E., additional, Hari, Anjali, additional, Bernstein, Megan, additional, Chang, Jenny, additional, Ziogas, Argyrios, additional, Pearre, Diana C., additional, and Tewari, Krishnansu S., additional

Published
2021
Full Text
View/download PDF

206. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062).

Author

Tewari, Krishnansu S and Tewari, Krishnansu S

Abstract

To isolate circulating tumor cells (CTC) from women with advanced cervical cancer and estimate the impact of CTCs and treatment on overall survival and progression-free survival (PFS). A total of 7.5 mL of whole blood was drawn pre-cycle 1 and 36 days post-cycle 1 from patients enrolled on Gynecologic Oncology Group 0240, the phase III randomized trial that led directly to regulatory approval of the antiangiogenesis drug, bevacizumab, in women with recurrent/metastatic cervical cancer. CTCs (defined as anti-cytokeratin+/anti-CD45- cells) were isolated from the buffy coat layer using an anti-EpCAM antibody-conjugated ferrofluid and rare earth magnet, and counted using a semiautomated fluorescence microscope. The median pre-cycle 1 CTC count was 7 CTCs/7.5 mL whole blood (range, 0-18) and, at 36 days posttreatment, was 4 (range, 0-17). The greater the declination in CTCs between time points studied, the lower the risk of death [HR, 0.87; 95% confidence interval (CI), 0.79-0.95)]. Among patients with high (≥ median) pretreatment CTCs, bevacizumab treatment was associated with a reduction in the hazard of death (HR, 0.57; 95% CI, 0.32-1.03) and PFS (HR, 0.59; 95% CI, 0.36-0.96). This effect was not observed with low (< median) CTCs. CTCs can be isolated from women with advanced cervical cancer and may have prognostic significance. A survival benefit conferred by bevacizumab among patients with high pretreatment CTCs may reflect increased tumor neovascularization and concomitant vulnerability to VEGF inhibition. These data support studying CTC capture as a potential predictive biomarker.

Published
2020

207. Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.

Author

Tewari, Krishnansu S and Tewari, Krishnansu S

Abstract

ObjectiveTo explore the relationship between tumor size and response to combined anti-vascular targeted therapy using the anti-angiogenesis inhibitor, bevacizumab, and the tubulin-binding vascular disrupting agent, fosbretabulin.MethodsAn exploratory, post-hoc analysis of the randomized phase II trial, Gynecologic Oncology Group-0186I, was performed. One hundred and seven patients with recurrent ovarian carcinoma, treated with up to 3 prior regimens, were randomized to bevacizumab 15 mg/kg body weight with or without intravenous fosbretabulin 60 mg/m2 body surface area every 21 days until progression or unacceptable toxicity. The primary analysis favored the combination (HR 0.69; 95% CI, 0.47-1.00; p = .049) [Monk BJ, et al. J Clin Oncol 2016;34:2279-86]. The Cox proportional hazards model was used to estimate the treatment effect in various subpopulations.ResultsWith extended follow-up, the median PFS for bevacizumab plus fosbretabulin was 7.6 months as compared to 4.8 months with bevacizumab alone (HR 0.74; 90% CI, 0.54-1.02). Overall survival was similar in the experimental and control arms (25.2 vs 24.4 mos, respectively, HR 0.85; 90% CI, 0.59-1.22; p = .461). Eighty-one patients had measurable disease and median tumor size was 5.7 cm. In the ≤5.7 cm subgroup, the HR for progression or death was 0.77 (90% CI 0.45-1.31). Patients with tumors >5.7 cm (n = 40) had a HR for progression or death of 0.55; 90% CI, 0.32-0.96; p = .075).ConclusionsAlthough no significant survival benefit was observed, the trend showing a reduced HR for progression or death with increasing tumor size when fosbretabulin is added to bevacizumab compared to bevacizumab alone warrants further study.

Published
2020

208. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)

Author

Miller, David S., primary, Filiaci, Virginia L., additional, Mannel, Robert S., additional, Cohn, David E., additional, Matsumoto, Takashi, additional, Tewari, Krishnansu S., additional, DiSilvestro, Paul, additional, Pearl, Michael L., additional, Argenta, Peter A., additional, Powell, Matthew A., additional, Zweizig, Susan L., additional, Warshal, David P., additional, Hanjani, Parviz, additional, Carney, Michael E., additional, Huang, Helen, additional, Cella, David, additional, Zaino, Richard, additional, and Fleming, Gini F., additional

Published
2020
Full Text
View/download PDF

209. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)

Author

Tewari, Krishnansu S., primary, Sill, Michael W., additional, Monk, Bradley J., additional, Penson, Richard T., additional, Moore, David H., additional, Lankes, Heather A., additional, Ramondetta, Lois M., additional, Landrum, Lisa M., additional, Randall, Leslie M., additional, Oaknin, Ana, additional, Leitao, Mario M., additional, Eisenhauer, Eric L., additional, DiSilvestro, Paul, additional, Van Le, Linda, additional, Pearl, Michael L., additional, Burke, James J., additional, Salani, Ritu, additional, Richardson, Debra L., additional, Michael, Helen E., additional, Kindelberger, David W., additional, and Birrer, Michael J., additional

Published
2020
Full Text
View/download PDF

210. Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study

Author

Tewari, Krishnansu S., primary, Sill, Michael W., additional, Coleman, Robert L., additional, Aghajanian, Carol, additional, Mannel, Robert, additional, DiSilvestro, Paul A., additional, Powell, Matthew, additional, Randall, Leslie M., additional, Farley, John, additional, Rubin, Stephen C., additional, and Monk, Bradley J., additional

Published
2020
Full Text
View/download PDF

214. Contributors

Author

Bidus, Michael A., primary, Brewster, Wendy R., additional, Chase, Dana M., additional, Chu, Christina S., additional, Clarke-Pearson, Daniel L., additional, Cohn, David E., additional, Coleman, Robert L., additional, Copeland, Larry J., additional, Creasman, William T., additional, Di Saia, Philip J., additional, Eisenhauer, Eric L., additional, Elkas, John C., additional, Fowler, Jeffrey M., additional, Gemignani, Mary L., additional, Ko, Emily M., additional, Landrum, Lisa M., additional, Mannel, Robert S., additional, Mathews, Cara A., additional, Larry Maxwell, G., additional, Mcmeekin, D. Scott, additional, Miller, David Scott, additional, Monk, Bradley J., additional, Mutch, David G., additional, Rose, G. Scott, additional, Rubin, Stephen C., additional, Salani, Ritu, additional, Schilder, Jeanne M., additional, Slomovitz, Brain M., additional, Sood, Anil K., additional, Soper, John T., additional, Stehman, Frederick B., additional, Tewari, Krishnansu S., additional, Walker, Joan L., additional, Wenzel, Lari B., additional, Westin, Shannon N., additional, Wong, Siu-Fun, additional, Yashar, Catheryn M., additional, and Zuna, Rosemary E., additional

Published
2012
Full Text
View/download PDF

223. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218

Author

Alvarez Secord, Angeles, primary, Bell Burdett, Kirsten, additional, Owzar, Kouros, additional, Tritchler, David, additional, Sibley, Alexander B., additional, Liu, Yingmiao, additional, Starr, Mark D., additional, Brady, J. Chris, additional, Lankes, Heather A., additional, Hurwitz, Herbert I., additional, Mannel, Robert S., additional, Tewari, Krishnansu S., additional, O'Malley, David M., additional, Gray, Heidi, additional, Bakkum-Gamez, Jamie N., additional, Fujiwara, Keiichi, additional, Boente, Matthew, additional, Deng, Wei, additional, Burger, Robert A., additional, Birrer, Michael J., additional, and Nixon, Andrew B., additional

Published
2020
Full Text
View/download PDF

227. Contributors

Author

Bidus, Michael A., primary, Brewster, Wendy R., additional, Chu, Christina S., additional, Clarke-Pearson, Daniel L., additional, Coleman, Robert L., additional, Copeland, Larry J., additional, Creasman, William T., additional, DiSaia, Philip J., additional, Fiorica, James V., additional, Kaplan, Keith J., additional, Mannel, Robert S., additional, McMeekin, D. Scott, additional, Monk, Bradley J., additional, Mutch, David G., additional, Rose, G. Scott, additional, Rubin, Stephen C., additional, Slomovitz, Brain M., additional, Soper, John T., additional, Stehman, Frederick B., additional, Sunde, Jan S., additional, Tewari, Krishnansu S., additional, Walker, Joan L., additional, Wenzel, Lari B., additional, Yashar, Catheryn, additional, Zahn, Christopher M., additional, and Zuna, Rosemary E., additional

Published
2007
Full Text
View/download PDF

230. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer

Author

Coleman, Robert L., primary, Spirtos, Nick M., additional, Enserro, Danielle, additional, Herzog, Thomas J., additional, Sabbatini, Paul, additional, Armstrong, Deborah K., additional, Kim, Jae-Weon, additional, Park, Sang-Yoon, additional, Kim, Byoung-Gie, additional, Nam, Joo-Hyun, additional, Fujiwara, Keiichi, additional, Walker, Joan L., additional, Casey, Ann C., additional, Alvarez Secord, Angeles, additional, Rubin, Steve, additional, Chan, John K., additional, DiSilvestro, Paul, additional, Davidson, Susan A., additional, Cohn, David E., additional, Tewari, Krishnansu S., additional, Basen-Engquist, Karen, additional, Huang, Helen Q., additional, Brady, Mark F., additional, and Mannel, Robert S., additional

Published
2019
Full Text
View/download PDF

232. Targeted treatment of advanced ovarian cancer: spotlight on rucaparib

Author

Pearre,Diana Cholakian and Tewari,Krishnansu S

Subjects
endocrine system diseases, Therapeutics and Clinical Risk Management, female genital diseases and pregnancy complications
Abstract

Diana C Pearre, Krishnansu S Tewari Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of California, Irvine Medical Center, Orange, CA, USA Abstract: The last 2 years have ushered in a new era in ovarian cancer therapy with the US Food and Drug Administration’s (FDA) approval of poly-ADP ribose polymerase (PARP) inhibitors (PARPi). One of the deadliest cancers that women experience, ovarian cancer, is most often diagnosed in advanced stages. Although cytoreductive surgery and (platinum/taxane-based) chemotherapy can place the majority of patients into remission, most will experience a relapse of their disease in their lifetime. This has led to studies exploring the benefits and efficacy of maintenance treatment. This review will briefly discuss the history of maintenance therapy as well as focus on the FDA’s approval of rucaparib and its companion tumor profiling test, in the US. It will describe how women with deleterious mutations in the BRCA gene, through their inherent deficiency in homologous recombination, presented scientists with a target to exploit through a concept known as synthetic lethality. Not only did this lead to a targeted treatment for BRCA mutation carriers but for other patients with deficiencies in homologous recombination and, more broadly, also in platinum-sensitive patients. The focus of this review will be on rucaparib in the US, approved for both maintenance of platinum-sensitive recurrent ovarian cancer and treatment in the third-line setting and beyond. It has the broadest indication amongst the three PARPi in ovarian cancer. Furthermore, the ongoing trials using rucaparib in ovarian cancer and other disease types will be discussed. Keywords: BRCA, PARP inhibitor, targeted therapy, rucaparib, ovarian cancer

Published
2018

234. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

Author

Tewari, Krishnansu S and Tewari, Krishnansu S

Abstract

PurposeWe report the final, protocol-specified analysis of overall survival (OS) in GOG-0218, a phase III, randomized trial of bevacizumab in women with newly diagnosed ovarian, fallopian tube, or primary peritoneal carcinoma.MethodsA total of 1,873 women with incompletely resected stage III to IV disease were randomly assigned 1:1:1 to six 21-day cycles of intravenous carboplatin (area under the concentration v time curve 6) and paclitaxel (175 mg/m2) versus chemotherapy plus concurrent bevacizumab (15 mg/kg, cycles 2 to 6) versus chemotherapy plus concurrent and maintenance bevacizumab (cycles 2 to 22). Inclusion criteria included a Gynecologic Oncology Group performance status of 0 to 2 and no history of clinically significant vascular events or evidence of intestinal obstruction. OS was analyzed in the intention-to-treat population. A total of 1,195 serum and/or tumor specimens were sequenced for BRCA1/2 and damaging mutations in homologous recombination repair (HRR) genes. Intratumoral microvessel density was studied using CD31 immunohistochemistry.ResultsMedian follow-up was 102.9 months. Relative to control (n = 625), for patients receiving bevacizumab-concurrent (n = 625), the hazard ratio (HR) of death was 1.06 (95% CI, 0.94 to 1.20); for bevacizumab-concurrent plus maintenance (n = 623), the HR was 0.96 (95% CI, 0.85 to 1.09). Disease-specific survival was not improved in any arm. No survival advantage was observed after censoring patients who received bevacizumab at crossover or as second line. Median OS for stage IV bevacizumab-concurrent plus maintenance was 42.8 v 32.6 months for stage IV control (HR, 0.75; 95% CI, 0.59 to 0.95). Relative to wild type, the HR for death for BRCA1/2 mutated carcinomas was 0.62 (95% CI, 0.52 to 0.73), and for non-BRCA1/2 HRR, the HR was 0.65 (95% CI, 0.51 to 0.85). BRCA1/2, HRR, and CD31 were not predictive of bevacizumab activity.ConclusionNo survival differences were observed for patients who received bevacizumab compar

Published
2019

236. RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.

Author

O'Malley, David M, Randall, Leslie M, Jackson, Camille Gunderson, Coleman, Robert L, Hays, John L, Moore, Kathleen N, Naumann, R Wendel, Rocconi, Rodney P, Slomovitz, Brian M, Tewari, Krishnansu S, Ancukiewicz, Marek, Feliu, Waldo Ortuzar, and Monk, Bradley J

Abstract

Balstilimab (anti-programmed death 1) and zalifrelimab (anti-CTLA-4) are two new checkpoint inhibitors that have emerged as promising investigational agents for the treatment of cervical cancer, particularly in the setting of previously-treated, recurrent/metastatic disease. Here we describe the rationale and design of RaPiDS (NCT03894215), a two-arm Phase II study evaluating the safety, tolerability and efficacy of balstilimab administered alone or in combination with zalifrelimab in patients with advanced cervical cancer who progressed after first-line, platinum-based chemotherapy. Patients will be randomized in a 1:1 ratio. The primary end point is objective response rate, and key secondary objectives include safety, duration of response, progression-free survival, overall survival and quality of life outcomes. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

239. Survival With Cemiplimab in Recurrent Cervical Cancer.

Author

Tewari, Krishnansu S., Monk, Bradley J., Vergote, Ignace, Miller, Austin, de Melo, Andreia C., Kim, Hee-Seung, Kim, Yong Man, Lisyanskaya, Alla, Samouëlian, Vanessa, Lorusso, Domenica, Damian, Fernanda, Chang, Chih-Long, Gotovkin, Evgeniy A., Takahashi, Shunji, Ramone, Daniella, Pikiel, Joanna, Maćkowiak-Matejczyk, Beata, Alía, Eva M. Guerra, Colombo, Nicoletta, and Makarova, Yulia

Published
2022
Full Text
View/download PDF

241. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer

Author

Tewari, Krishnansu S., primary, Burger, Robert A., additional, Enserro, Danielle, additional, Norquist, Barbara M., additional, Swisher, Elizabeth M., additional, Brady, Mark F., additional, Bookman, Michael A., additional, Fleming, Gini F., additional, Huang, Helen, additional, Homesley, Howard D., additional, Fowler, Jeffrey M., additional, Greer, Benjamin E., additional, Boente, Matthew, additional, Liang, Sharon X., additional, Ye, Chenglin, additional, Bais, Carlos, additional, Randall, Leslie M., additional, Chan, John K., additional, Ferriss, J. Stuart, additional, Coleman, Robert L., additional, Aghajanian, Carol, additional, Herzog, Thomas J., additional, DiSaia, Philip J., additional, Copeland, Larry J., additional, Mannel, Robert S., additional, Birrer, Michael J., additional, and Monk, Bradley J., additional

Published
2019
Full Text
View/download PDF

242. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

Author

Matei, Daniela, primary, Filiaci, Virginia, additional, Randall, Marcus E., additional, Mutch, David, additional, Steinhoff, Margaret M., additional, DiSilvestro, Paul A., additional, Moxley, Katherine M., additional, Kim, Yong M., additional, Powell, Matthew A., additional, O’Malley, David M., additional, Spirtos, Nick M., additional, Small, William, additional, Tewari, Krishnansu S., additional, Richards, William E., additional, Nakayama, John, additional, Matulonis, Ursula A., additional, Huang, Helen Q., additional, and Miller, David S., additional

Published
2019
Full Text
View/download PDF

244. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Author

Walker, Joan L., primary, Brady, Mark F., additional, Wenzel, Lari, additional, Fleming, Gini F., additional, Huang, Helen Q., additional, DiSilvestro, Paul A., additional, Fujiwara, Keiichi, additional, Alberts, David S., additional, Zheng, Wenxin, additional, Tewari, Krishnansu S., additional, Cohn, David E., additional, Powell, Matthew A., additional, Van Le, Linda, additional, Davidson, Susan A., additional, Gray, Heidi J., additional, Rose, Peter G., additional, Aghajanian, Carol, additional, Myers, Tashanna, additional, Alvarez Secord, Angeles, additional, Rubin, Stephen C., additional, and Mannel, Robert S., additional

Published
2019
Full Text
View/download PDF

245. Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma

Author

Rose, Peter G., primary, Java, James J., additional, Salani, Ritu, additional, Geller, Melissa A., additional, Secord, Angeles Alvarez, additional, Tewari, Krishnansu S., additional, Bender, David P., additional, Mutch, David G., additional, Friedlander, Michael L., additional, Van Le, Linda, additional, Method, Michael W., additional, Hamilton, Chad A., additional, Lee, Roger B., additional, Wenham, Robert M., additional, Guntupalli, Saketh R., additional, Markman, Maurie, additional, Muggia, Franco M., additional, Armstrong, Deborah K., additional, Bookman, Michael A., additional, Burger, Robert A., additional, and Copeland, Larry J., additional

Published
2019
Full Text
View/download PDF

248. Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study

Author

Hensley, Martee L., primary, Enserro, Danielle, additional, Hatcher, Helen, additional, Ottevanger, Petronella B., additional, Krarup-Hansen, Anders, additional, Blay, Jean-Yves, additional, Fisher, Cyril, additional, Moxley, Katherine M., additional, Lele, Shashikant B., additional, Lea, Jayanthi S., additional, Tewari, Krishnansu S., additional, Thaker, Premal H., additional, Zivanovic, Oliver, additional, O’Malley, David M., additional, Robison, Katina, additional, and Miller, David S., additional

Published
2018
Full Text
View/download PDF

249. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study

Author

Tew, William P., primary, Sill, Michael W., additional, Walker, Joan L., additional, Secord, Angeles Alvarez, additional, Bonebrake, Albert J., additional, Schilder, Jeanne M., additional, Stuckey, Ashley, additional, Rice, Laurel, additional, Tewari, Krishnansu S., additional, and Aghajanian, Carol A., additional

Published
2018
Full Text
View/download PDF

250. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study

Author

Van Le, Linda, Quinn, Michael C.J., Krivak, Thomas C., Lankes, Heather, Berchuck, Andrew, Wenham, Robert M., Tritchler, David, Backes, Floor J., Bookman, Michael A., Kaufman, Kenneth M., Moore, Kathleen N., Tewari, Krishnansu S., Lee, Roger B., Armstrong, Deborah K., Kesterson, Joshua P., and Birrer, Michael J.

Subjects
endocrine system diseases, female genital diseases and pregnancy complications
Abstract

This study evaluated single nucleotide polymorphisms (SNPs) associated with progression free (PFS) and overall survival (OS) in patients with advanced stage serous EOC.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results